<i>NORAD</i>-Regulated Signaling Pathways in Breast Cancer Progression
Long non-coding RNA activated by DNA damage (<i>NORAD</i>) has recently been associated with pathologic mechanisms underlying cancer progression. Due to <i>NORAD</i>’s extended range of interacting partners, there has been contradictory data on its oncogenic or tumor suppress...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/3/636 |
| _version_ | 1797318968782880768 |
|---|---|
| author | Ana Maria Capela Carlota Tavares-Marcos Hugo F. Estima-Arede Sandrina Nóbrega-Pereira Bruno Bernardes de Jesus |
| author_facet | Ana Maria Capela Carlota Tavares-Marcos Hugo F. Estima-Arede Sandrina Nóbrega-Pereira Bruno Bernardes de Jesus |
| author_sort | Ana Maria Capela |
| collection | DOAJ |
| description | Long non-coding RNA activated by DNA damage (<i>NORAD</i>) has recently been associated with pathologic mechanisms underlying cancer progression. Due to <i>NORAD</i>’s extended range of interacting partners, there has been contradictory data on its oncogenic or tumor suppressor roles in BC. This review will summarize the function of <i>NORAD</i> in different BC subtypes and how <i>NORAD</i> impacts crucial signaling pathways in this pathology. Through the preferential binding to pumilio (PUM) proteins PUM1 and PUM2, <i>NORAD</i> has been shown to be involved in the control of cell cycle, angiogenesis, mitosis, DNA replication and transcription and protein translation. More recently, <i>NORAD</i> has been associated with PUM-independent roles, accomplished by interacting with other ncRNAs, mRNAs and proteins. The intricate network of <i>NORAD</i>-mediated signaling pathways may provide insights into the potential design of novel unexplored strategies to overcome chemotherapy resistance in BC treatment. |
| first_indexed | 2024-03-08T04:00:03Z |
| format | Article |
| id | doaj.art-d8c76e4de95a4224b4494216a074d1da |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T04:00:03Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d8c76e4de95a4224b4494216a074d1da2024-02-09T15:09:25ZengMDPI AGCancers2072-66942024-02-0116363610.3390/cancers16030636<i>NORAD</i>-Regulated Signaling Pathways in Breast Cancer ProgressionAna Maria Capela0Carlota Tavares-Marcos1Hugo F. Estima-Arede2Sandrina Nóbrega-Pereira3Bruno Bernardes de Jesus4Department of Medical Sciences, Institute of Biomedicine—iBiMED, University of Aveiro, 3810-193 Aveiro, PortugalDepartment of Medical Sciences, Institute of Biomedicine—iBiMED, University of Aveiro, 3810-193 Aveiro, PortugalDepartment of Medical Sciences, Institute of Biomedicine—iBiMED, University of Aveiro, 3810-193 Aveiro, PortugalDepartment of Medical Sciences, Institute of Biomedicine—iBiMED, University of Aveiro, 3810-193 Aveiro, PortugalDepartment of Medical Sciences, Institute of Biomedicine—iBiMED, University of Aveiro, 3810-193 Aveiro, PortugalLong non-coding RNA activated by DNA damage (<i>NORAD</i>) has recently been associated with pathologic mechanisms underlying cancer progression. Due to <i>NORAD</i>’s extended range of interacting partners, there has been contradictory data on its oncogenic or tumor suppressor roles in BC. This review will summarize the function of <i>NORAD</i> in different BC subtypes and how <i>NORAD</i> impacts crucial signaling pathways in this pathology. Through the preferential binding to pumilio (PUM) proteins PUM1 and PUM2, <i>NORAD</i> has been shown to be involved in the control of cell cycle, angiogenesis, mitosis, DNA replication and transcription and protein translation. More recently, <i>NORAD</i> has been associated with PUM-independent roles, accomplished by interacting with other ncRNAs, mRNAs and proteins. The intricate network of <i>NORAD</i>-mediated signaling pathways may provide insights into the potential design of novel unexplored strategies to overcome chemotherapy resistance in BC treatment.https://www.mdpi.com/2072-6694/16/3/636lncRNAs<i>NORAD</i>pumiliobreast cancerchemotherapy resistance |
| spellingShingle | Ana Maria Capela Carlota Tavares-Marcos Hugo F. Estima-Arede Sandrina Nóbrega-Pereira Bruno Bernardes de Jesus <i>NORAD</i>-Regulated Signaling Pathways in Breast Cancer Progression Cancers lncRNAs <i>NORAD</i> pumilio breast cancer chemotherapy resistance |
| title | <i>NORAD</i>-Regulated Signaling Pathways in Breast Cancer Progression |
| title_full | <i>NORAD</i>-Regulated Signaling Pathways in Breast Cancer Progression |
| title_fullStr | <i>NORAD</i>-Regulated Signaling Pathways in Breast Cancer Progression |
| title_full_unstemmed | <i>NORAD</i>-Regulated Signaling Pathways in Breast Cancer Progression |
| title_short | <i>NORAD</i>-Regulated Signaling Pathways in Breast Cancer Progression |
| title_sort | i norad i regulated signaling pathways in breast cancer progression |
| topic | lncRNAs <i>NORAD</i> pumilio breast cancer chemotherapy resistance |
| url | https://www.mdpi.com/2072-6694/16/3/636 |
| work_keys_str_mv | AT anamariacapela inoradiregulatedsignalingpathwaysinbreastcancerprogression AT carlotatavaresmarcos inoradiregulatedsignalingpathwaysinbreastcancerprogression AT hugofestimaarede inoradiregulatedsignalingpathwaysinbreastcancerprogression AT sandrinanobregapereira inoradiregulatedsignalingpathwaysinbreastcancerprogression AT brunobernardesdejesus inoradiregulatedsignalingpathwaysinbreastcancerprogression |